Novartis manufacturing facility in North Carolina gets FDA all-clear to produce, ship gene therapies

Just one day after Vas Narasimhan announced $1 billion in cuts amid a company-wide restructuring, the American-Swiss pharma received FDA clearance to produce its spinal muscular atrophy drug Zolgensma out of its North Carolina manufacturing facility.